All In Biotech

Drug Trial Radar · NCT03981796

A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)

Last checked: Nov 19, 2026Latest source record: Sep 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 785 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

785

Actual

Start

Jul 18, 2019

Primary completion

Nov 26, 2026

Study completion Nov 26, 2026

Sponsor

Lead sponsor
Tesaro, Inc.GSK (GSK)
Sponsor type
Industry
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation
First posted
Jun 11, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 2 part study. Part 1 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab versus placebo plus carboplatin-paclitaxel followed by placebo; and Part 2 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab plus niraparib versus placebo plus carboplatin-paclitaxel followed by placebo in participants with recurrent or primary advanced (Stage III or IV) endometrial cancer.

Conditions

  • Neoplasms

Interventions

  • DostarlimabBiological

    Participants will be administered dostarlimab

  • Placebo matching dostarlimabDrug

    Participants will be administered placebo matching dostarlimab

  • CarboplatinDrug

    Participants will be administered carboplatin

  • PaclitaxelDrug

    Participants will be administered paclitaxel

  • NiraparibDrug

    Participants will be administered niraparib

  • Placebo matching NiraparibDrug

    Participants will be administered placebo matching Niraparib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts 1 and 2: Progression-Free Survival (PFS) - investigator assessmentTime frame: Up to 6 years
  2. Part 1: Overall survivalTime frame: Up to 6 years

Locations

169 sites in 20 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Scottsdale, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Newport Beach, California

  • GSK Investigational Site

    Palo Alto, California

  • GSK Investigational Site

    Deerfield Beach, Florida

  • GSK Investigational Site

    Jacksonville, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    Augusta, Georgia

  • GSK Investigational Site

    Savannah, Georgia

  • GSK Investigational Site

    Hinsdale, Illinois

  • GSK Investigational Site

    Zion, Illinois

  • GSK Investigational Site

    Fort Wayne, Indiana

  • GSK Investigational Site

    Indianapolis, Indiana

  • GSK Investigational Site

    Indianapolis, Indiana

  • GSK Investigational Site

    Iowa City, Iowa

  • GSK Investigational Site

    Lexington, Kentucky

  • GSK Investigational Site

    Covington, Louisiana

  • GSK Investigational Site

    New Orleans, Louisiana

  • GSK Investigational Site

    Shreveport, Louisiana

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Springfield, Massachusetts

  • GSK Investigational Site

    Detroit, Michigan

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Lebanon, New Hampshire

  • GSK Investigational Site

    Albuquerque, New Mexico

  • GSK Investigational Site

    Rio Rancho, New Mexico

  • GSK Investigational Site

    Albany, New York

  • GSK Investigational Site

    Mineola, New York

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    The Bronx, New York

  • GSK Investigational Site

    Charlotte, North Carolina

  • GSK Investigational Site

    Durham, North Carolina

  • GSK Investigational Site

    Kernersville, North Carolina

  • GSK Investigational Site

    Mount Airy, North Carolina

  • GSK Investigational Site

    Winston-Salem, North Carolina

Showing 40 of 169 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.